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Methods to systematically test drugs against all possible proteins
in a cell are needed to identify the targets underlying their
therapeutic action and unwanted effects. Here, we show that a
genome-wide drug-induced haploinsufficiency screen by using
yeast can reveal drug mode of action in yeast and can be used to
predict drug mode of action in human cells. We demonstrate that
dihydromotuporamine C, a compound in preclinical development
that inhibits angiogenesis and metastasis by an unknown mech-
anism, targets sphingolipid metabolism. The systematic, unbiased
and genome-wide nature of this technique makes it attractive as a
general approach to identify cellular pathways affected by drugs.
Cell-based screening is increasingly used to identify chemicalsthat can suppress or enhance particular cellular phenotypes.
Chemicals identified by phenotypic screening are valuable chem-
ical genetic tools to study complex cellular processes and are
often attractive candidates for drug development (1–3). Identi-
fication of the mechanism of action of these chemicals is an
integral part of the chemical genetic approach and is also critical
for evaluating and optimizing therapeutic agents, yet no system-
atic target identification approach exists (3). The classical
method is to purify the target from cellular extracts by using
immobilized or radiolabeled versions of the chemical or to guess
candidates and test them one by one in binding or functional
assays (3). However, without prior knowledge of the pathways
affected by the drug, these approaches have met with little
success and systematic genomic and proteomic methods to test
a wide range of drugs against all possible targets in a cell are
clearly needed.
The budding yeast Saccharomyces cerevisiae has been pro-
posed as a tool for identifying human drug targets because
40% of yeast proteins share some conserved sequence with at
least one known or predicted human protein, including several
hundred genes implicated in human disease (4, 5). Recent
technological advances in yeast genomics, including gene expres-
sion profiling, chemical-genetic synthetic profiling, and drug-
induced haploinsufficiency, show promise as tools to study
proteins and pathways affected by drugs at a genome-wide level
(4, 5). Drug-induced haploinsufficiency occurs when lowering
the dosage of a single gene from two copies to one copy in diploid
cells results in a heterozygote that displays increased drug
sensitivity compared with wild-type strains (6). Giaever et al. (6)
pooled 233 ‘‘bar-coded’’ heterozygous yeast strains, grew them
competitively in the presence of a drug whose target in yeast cells
was known, and successfully used DNA microarrays to identify
the heterozygous drug target strain whose growth was compro-
mised in the presence of the drug. Here, we asked whether
drug-induced haploinsufficiency could be applied genome-wide
to identify the mode of action of a drug with an unknown target.
We used dihydromotuporamine C (dhMotC) (Fig. 1A), a mem-
ber of the motuporamine family of agents discovered in a
phenotypic screen for small molecules that inhibit invasion of
human carcinoma cell lines (2, 7). The motuporamines inhibit
the formation of invadopodia, decrease tumor cell motility, and
alter the organization of filamentous actin at the cell margin (2).
Identifying the mechanism of action of dhMotC is critical for
evaluating its potential for cancer therapy but it is a difficult task,
because dhMotC has no other known biological activities, it does
not resemble other bioactive molecules, and its chemical struc-
ture revealed no clues to guide target identification.
By using a genome-wide haploinsufficiency screen, we show
that dhMotC targets sphingolipid metabolism, resulting in de-
creased ceramide levels in yeast. Furthermore, exogenous cer-
amide partially rescues the effect of dhMotC on human cell
survival, demonstrating that systematic genome-wide analysis of
drug effects in yeast can be used to elucidate the mechanism of
action of drugs in yeast and in human cells.
Materials and Methods
Reagents. dhMotC was a generous gift of D. Williams (University
of British Columbia). It was synthesized as described (7) and was
solubilized in DMSO. Dihydrosphingosine (DHS) and C6-
ceramide were purchased from Sigma.
Yeast Strains, Media, and Genetic Manipulations. The diploid het-
erozygous deletion mutants generated by the International
Deletion Consortium (8) were obtained from Research Genet-
icsInvitrogen. BY4743 was used as the diploid wild-type con-
trol. TDY2037 (wild-type) and TDY2038 (csg2) MAT haploid
strains were described (9). Yeast was grown on standard rich
medium [yeast extractpeptonedextrose (YPD)] as described
(10).
Individual Growth Rate Analysis. Growth rates of strains were
measured under various drug conditions essentially as described
(6). Cells were diluted from an overnight culture to an OD600 of
0.01 and were allowed to grow until the OD600 reached 0.05
(t  0) to ensure that cells were in logarithmic phase. Drug was
added and growth rates were measured by determination of
OD600 as a function of time by using a Pharmacia Biotech
Ultrospec 3000 or a Tecan Sunrise plate reader. Growth curves
were carried out in triplicate and curves shown are averages of
three experiments with error bars representing 1 SD.
Drug-Induced Haploinsufficiency Screen. The deletion mutant ar-
rays (DMA) were propagated on rich liquid medium containing
G418 (200 mgliter, GIBCOBRL). The DMA were transferred
by hand with a model VP408FH 96-floating pin replicator (V &
P Scientific, San Diego) and a VP380 colony copier (V & P
Scientific) into 96-well plates containing 100 l of liquid YPD
and were grown overnight at 25°C to saturation. Replicator
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sterilization procedures were as described (11). Saturated cul-
tures compensated for differences in growth rate between
strains, to ensure that roughly equal amounts of cells were
deposited on the agar plates. After 24 h, the DMA were pinned
onto plates (OmniTray, Nunc) containing YPD-agar and DMSO
(6 lml) or 60 M dhMotC and DMSO (6 lml). DMA were
arrayed at high density by using a BioRobotics TAS1 robot with
a 0.4-mm diameter 96-pin tool that spots 20 nl or 250 cells.
Strains were pinned in duplicate with a density of 1,536 per plate.
Pins were sterilized by agitating for 30 s in 10% bleach followed
by 95% ethanol for 15 s and drying with warm air for 15 s. Plates
were grown at 25°C and strains were scored for growth, slow
growth, or no growth, compared with no drug over a period of
4 days.
Integrative Growth Curve Difference (IGCD) Analysis. We analyzed
growth curves for 29 strains, each grown without drug and in the
presence of 20 M dhMotC. OD600 measurements of cell density
were taken hourly for 10 time points. The typical level of
replication was three growth curves per strain per condition, for
a total of six curves per strain. The cultures underwent expo-
nential growth during the time points and conditions studied.
Therefore, we used a log-transformed linear model to relate
growth to time by using the model: log OD600 g(t)  0g  1g M
 2g t  3g tM  g where g indicates the strain, M indicates
the presence of dhMotC, and t indicates time. The intercept of
this model, equal to 0g  1g M, captures early growth and 1g
is the adjustment due to dhMotC. The slope, equal to 2g  3g
M, reflects the steady-state doubling time and 3g is the adjust-
ment due to dhMotC. Both the intercept and the slope were
modified by the presence of dhMotC, indicating early and
persistent effects on growth, respectively. The dhMotC effect on
growth was highly statistically significant (P  1011) for all 29
strains evaluated, when quantified by using an F test for a
restricted model that does not include the dhMotC terms. Strains
were ranked according to the cumulative dhMotC effect or
IGCDs, denoted Dg, as measured by the area between the
expected growth curves with and without drug. Because these
curves were linear on the transformed scale, the integral has the
following simple form Dg (T1,g T 22) 3,g. Therefore, the
final quantitative measure of cumulative dhMotC effect on each
strain is the estimated value of Dg, obtained by evaluating
the above expression at the estimated dhMotC regression
coefficients.
Immunolocalization Studies. Cells were grown to early log phase in
YPD at 25°C and treated with either DMSO, 60 M dhMotC,
or 60 M dhMotC plus 50 M DHS for 1.5 h. Cells were then
fixed in formaldehyde and were stained with rhodamine-
phalloidin (R-415, Molecular Probes) to visualize F-actin and
4,6-diamidino-2-phenylindole (Sigma) to visualize DNA as de-
scribed (12).
Whole-Cell Ceramide Isolation. Wild-type (TDY2037) and csg2
(TDY2038) cells were grown overnight in YPD to an OD600 near
1.0. Cells were diluted to 0.2–0.4 OD600 in YPD containing 10
Ciml (1 Ci  37 GBq) 3H-serine and were treated with either
5 M dhMotC or the equivalent amount of DMSO. After 8 h,
12 OD600 units of cells were harvested by centrifugation, were
washed with water, were dried thoroughly, and 20 volumes of
hexane:ethanol (95:5) were added. The cells were extracted by
bead beating and bath sonication. The resulting suspension was
centrifuged to remove cell debris. The hexane:ethanol fraction
was dried under nitrogen and was subjected to mild alkaline
hydrolysis in ethanol:water:ether:pyridine (15:15:5:1) with 0.1 M
KOH added. After 3 h at 37°C, the solution was neutralized by
the addition of 0.1 M acetic acid and was dried under nitrogen.
The dried extract was desalted by resuspension in water-
saturated butanol. An equal volume of water was added and the
butanol layer was extracted after centrifugation and was dried
under nitrogen. A total of 10 OD600 of each sample were run on
TLC plates by using chloroform:methanol:acetic acid
(95:4.5:0.5), the TLC plates were dried, and were rerun on the
same system. After the second run, the plates were sprayed with
10% CuSO4 in 8% phosphoric acid, were dried completely, and
were heated at 80° until the ceramide was visible. The ceramide
bands were scraped off the TLC plate and the amount of serine
incorporated into ceramide was determined by liquid scintilla-
tion counting.
Mammalian Cell Survival Assay. MDA-231 cells were plated at
10,000 cells per well in 96-well culture dishes and were allowed
to grow overnight. They were subsequently exposed to different
concentrations of dhMotC andor C6-ceramide (Sigma) for 24 h.
Cell survival was measured by using the (3-(4,5-dimethylthia-
zolyl-2)-2,5-diphenyltetrazolium bromide) assay (Sigma).
Database. For further information, refer to the Saccharomyces
Genome Database, which can be accessed at www.yeastgenome.
org.
Results
We developed a pathwaytarget identification procedure by
using drug-induced haploinsufficiency in yeast that consists of
five stages: (i) selection of a drug-induced phenotype; (ii)
systematic high-throughput phenotypic screen of a yeast het-
erozygous deletion diploid set for enhanced or suppressed
drug-induced phenotype; (iii) selection of potential pathways
targets based on quantitative ranking of drug sensitivity; (iv)
confirmation of drug mode of action in yeast; and (v) assessment
of cognate mode of action in the mammalian system.
Sensitivity of Yeast to dhMotC. As a prerequisite, treatment of
yeast with a drug of interest must cause a phenotype that is easily
scored, such as growth inhibition. dhMotC inhibited the growth
Fig. 1. Sensitivity of yeast to dhMotC. (A) Structural formula of dhMotC. (B)
Growth of wild-type (BY4743) strain (OD600) as a function of time in hours.
BY4743 was grown in YPD liquid culture with or without dhMotC treatment
as indicated. Growth curves were performed in triplicate and represent the
average of three experiments.
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of wild-type diploid yeast (BY4743) in liquid cultures in a
concentration-dependent manner (Fig. 1B). Concentrations60
M severely inhibited growth and resulted in a terminal phe-
notype that was not cell cycle-specific (data not shown). This
result suggests that dhMotC targets at least one gene product
involved in an essential function in S. cerevisiae.
Genome-Wide Drug-Induced Haploinsufficiency Screen. For high-
throughput phenotypic screening, a set of 5,000 heterozygous
diploid deletion strains covering most yeast genes was robotically
arrayed onto agar plates containing either DMSO (no drug
control) or a sublethal dhMotC concentration of 60 M. The
plates were incubated at 25°C and strain growth on DMSO- and
dhMotC-treated plates was compared over a period of 4 days. An
extended monitoring period was necessary for scoring of strains
that grew slowly because of their intrinsic haploinsufficiency.
The screen was carried out twice and strains displaying increased
sensitivity to dhMotC in both screens are shown in Table 1. The
list includes six essential genes and 15 nonessential genes impli-
cated in a variety of functions.
Quantitative Identification of Supersensitive Strains. To confirm and
quantitatively rank the sensitivity of the 21 strains, we carried out
automated quantitative liquid growth measurements under no-
drug conditions or at a concentration of dhMotC (20 M) that
causes only a small degree of growth inhibition (Fig. 2A).
Because many heterozygous yeast deletion strains exhibit a slow
growth phenotype or haploinsufficiency in rich culture medium
(6), it was necessary to compare growth profiles with and without
drug for each strain. We next established a model for ranking
strain sensitivity by using IGCDs (see Materials and Methods), a
technique unbiased by differences in growth rate between
strains.
As expected, all 21 strains were more sensitive to 20 M
dhMotC than the wild-type control, but most showed only minor
growth inhibition. However, two strains were clearly more
sensitive than others: lcb1LCB1 and tsc10TSC10 showed an
IGCD2-fold over wild type and were defined as supersensitive
(Fig. 2 C and D). Eight additional strains showed IGCD 1.5-
fold greater than wild type (Fig. 2E). Both LCB1 and TSC10 are
essential genes required for the biosynthesis of the sphingolipid
precursor sphingosine, suggesting that dhMotC targets a sphin-
golipid-dependent process.
dhMotC Targets Sphingolipid Biosynthesis. Sphingolipids are essen-
tial components of all eukaryotic cells, playing both structural
and regulatory roles (13, 14). The first committed step of
sphingolipid synthesis is the condensation of serine and palmi-
toyl CoA to 3-ketodihydrosphingosine catalyzed by serine palmi-
toyl transferase, composed of subunits encoded by LCB1 and
LCB2. The quantity of 3-ketodihydrosphingosine is then reduced
to DHS by 3-ketosphinganine reductase (Tsc10) encoded by
TSC10 and DHS is subsequently hydroxylated to phytosphin-
gosine (PHS) by DHS hydroxylase encoded by SUR2. PHS is
conjugated with C26-fattyacyl-CoA to form ceramide in a reac-
tion requiring the homologous and functionally redundant LAG1
and LAC1 (Fig. 3). In mammalian cells, the predominant long
Table 1. Heterozygous deletion strains sensitive to dhMotC
ORF Name Biological process†
YCL034W LSB5 Actin filament organization
YNL314W DAL82 Allantoin catabolism and transcription
initiation from polymerase II
promoter
YML099C ARG81 Arginine metabolism
YBR078W ECM33 Cell wall organization and biogenesis
YNL267W* PIK1* Cytokinesis, post-Golgi transport, and
signal transduction
YLR286C CTS1 Cytokinesis, completion of separation
YDL192W ARF1 ER-to-Golgi transport and intra-Golgi
transport
YBR290W BSD2 Heavy metal ion transport and protein
vacuolar targeting
YLR025W SNF7 Late endosome to vacuole transport
YHR147C MRPL6 Protein biosynthesis
YOL040C* RPS15* Protein biosynthesis
YAL005C SSA1 Protein folding and protein-nucleus
import, translocation
YIL047C SYG1 Signal transduction
YBR265W* TSC10* Sphingolipid biosynthesis
YMR296C* LCB1* Sphingolipid biosynthesis
YJR007W* SUI2* Translation initiation







†Biological process according to their Saccharomyces Genome Database
report.
Fig. 2. dhMotC sensitivity of heterozygous deletion strains identified in the
high-throughput screen. (A–D) Growth of wild-type (A), ylr294YLR294 (B),
tsc10TSC10 (C), and lcb1LCB1 (D) strains as a function of time in hours in YPD
liquid culture under two conditions: , no drug control (DMSO); Œ 20 M
dhMotC. Growth curves were preformed in triplicate, and OD600 was mea-
sured by using a Tecan Sunrise plate reader. Growth curves represents the
average of three experiments. (E) Plot of the IGCD for 21 heterozygous
deletion strains identified in the drug screen are represented by black bars.
The IGCD levels for the three additional heterozygous strains in the sphingo-
lipid pathway sensitive to dhMotC are represented by gray bars. The dashed
line represents 2-fold IGCD level used to define supersensitive strains.






chain base (LCB) is sphingosine (formed by desaturation of
DHS) rather than PHS. In addition to de novo synthesis, LCBs
and ceramide are produced both by this synthetic pathway and
by catabolism of complex sphingolipids that are major compo-
nents of cellular membranes. Sphingosine also plays an intra-
cellular signaling function by activating a Pkh1-Ypk1 kinase
cascade controlling the actin cytoskeleton (Fig. 3 and refs. 13 and
14). Pkh1 phosphorylates and activates several protein kinases,
including Ypk1 and Pkc1 (15, 16). PKH1 is a nonessential gene
that is genetically redundant with PKH2, and pkh1pkh2
double-deletion mutants are inviable (15, 16), whereas
pkh1D398Gpkh2 double mutants are viable and display actin
polarization defects (16). Although no genes of the sphingolipid
metabolism pathway other than LCB1 and TSC10 were identi-
fied in the high-throughput screen, the supersensitivity of lcb1
LCB1 and tsc10TSC10 to dhMotC motivated us to directly test
the sensitivity of additional heterozygous mutants (indicated in
Fig. 3). Whereas most strains did not display dhMotC sensitivity
above wild type, the ypk1YPK1 strain was supersensitive and
lcb2LCB2, sur2SUR2, and pkh1PKH1 strains showed
increased sensitivity to dhMotC when tested in the liquid growth
assay (Fig. 2E). The sensitivity of six mutants heterozygous for
deletions of genes involved in sphingolipid metabolism strongly
suggests that dhMotC either directly targets sphingolipid me-
tabolism or targets a pathway that is synthetically lethal in
combination with compromised sphingolipid synthesis.
To determine whether interference with sphingolipid biosyn-
thesis was important for growth inhibition by dhMotC, we asked
whether increased levels of sphingolipid biosynthetic interme-
diates could rescue the dhMotC sensitivity of wild-type cells.
Exogenous addition of DHS has been shown previously to rescue
genetic disruption of LCB1 (9, 17). We therefore tested the
effect of DHS addition to liquid growth medium and found that
DHS did not affect the growth of wild-type yeast but nearly
completely suppressed growth inhibition by dhMotC (Fig. 4A).
It has also been shown that lack of sphingosine synthesis results
in defects in the organization of the actin cytoskeleton that can
be rescued by exogenous DHS (17). Similarly, we found that
dhMotC treatment caused depolarization of the yeast actin cy-
toskeleton, a defect that was also rescued by exogenous DHS (Fig.
4B). Deletion of either CSG1 or CSG2, genes required for man-
nosylation of inositolphosphorylceramide-C, has been shown to
cause the accumulation of inositolphosphorylceramide-C and cer-
amide in cells (18, 19). We found that csg2mutant cells are almost
completely resistant to dhMotC treatment, indicating that similar to
exogenous DHS, elevated inositolphosphorylceramide-C andor
ceramide are protective against the effects of dhMotC (Fig. 4C).
Our analysis suggests that dhMotC directly affects the bio-
synthesis of sphingolipids in yeast. Therefore, we carried out
biochemical assays to determine which sphingolipid metabolic
intermediate might be affected by dhMotC. To address whether
dhMotC directly inhibits Tsc10, we analyzed sphingoid bases
from drug-treated cells. Whereas tsc10 mutants (with reduced-
function Tsc10) accumulate 3-ketosphinganine (9), treatment of
cells with dhMotC did not cause 3-ketosphinganine to accumu-
late, nor did it alter the steady state levels of DHS and PHS (data
not shown). Furthermore, in vitro activity of serine palmitoyl
transferase was not inhibited by dhMotC (data not shown).
These data indicate that dhMotC is not directly inhibiting serine
palmitoyl transferase or Tsc10. However, dhMotC reduced
cellular ceramide levels (data not shown). To investigate this
hypothesis further, we measured incorporation of 3H-serine into
ceramide during an 8-h labeling period with and without dh-
MotC (Fig. 4D). Wild-type cells treated with sublethal levels of
dhMotC have roughly half as much ceramide per cell after 8 h
as untreated wild-type cells. As expected, csg2 cells have
elevated levels of ceramide, and although dhMotC treatment of
csg2 cells also lowers ceramide levels, ceramide levels are still
above normal, confirming that elevated ceramide levels protect
csg2 cells from dhMotC. The fact that dhMotC lowers ceramide
levels in wild-type cells indicates that dhMotC directly targets
sphingolipid metabolism in yeast rather than a pathway that is
synthetic lethal with compromised sphingolipid metabolism.
If the mode of action of dhMotC is conserved between yeast
and mammalian cells, then treatment of human cells with
exogenous ceramide should rescue the effects of dhMotC.
Exposure of breast carcinoma MDA-231 cells to high concen-
trations (10 M) of dhMotC for an extended time (24 h) reduces
their survival (Fig. 4E). Addition of 10 or 50 nM C6-ceramide
had no effect on the survival of cells not exposed to dhMotC, but
10 nM C6-ceramide slightly increased survival and 50 nM
C6-ceramide increased by 4- to 5-fold the survival of cells
exposed to dhMotC (Fig. 4E). Higher ceramide concentrations
reduced the extent of the rescue (data not shown), possibly
because ceramide is known to induce apoptosis at higher con-
centrations (13, 20). These results indicate that modulation of
ceramide levels by dhMotC is relevant to its mechanism of action
in yeast and mammalian cells alike.
Discussion
We have applied a systematic approach for identifying candidate
drug targets and pathways in yeast that should be applicable to
any drug causing a scorable phenotype such as growth inhibition.
Importantly, this study indicates that the physiological process
that is affected by a drug in mammalian cells, in this case cancer
cell invasion, need not be recapitulated in yeast for the technique
to be considered. Of relevance is the cross-species conservation
of biochemical pathway function and not the specific phenotypic
consequence of pathway disruption in yeast versus human cells.
In this study, dhMotC was used as a test drug and the initial
high-throughput screen identified 21 heterozygous deletion
strains with increased sensitivity to dhMotC. Heterozygous gene
deletions that cause increased drug sensitivity are expected to
comprise essential genes whose products are direct drug targets
and essential or nonessential genes that exhibit synthetic inter-
Fig. 3. Schematic diagram of sphingolipid biosynthesis and sphingosine-
dependent kinase cascade in yeast and humans. Yeast genes are italic, and
yeast proteins are Roman. Human proteins are bold. Heterozygous yeast
strains tested for sensitivity to dhMotC are indicated by asterisks.
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actions with the drug target. Quantitative ranking of dhMotC
sensitivity in a subsequent liquid growth assay identified two
members of the sphingolipid biosynthesis pathway, lcb1LCB1
and tsc10TSC10, as supersensitive strains, clearly prioritizing
this pathway as the candidate target. Direct measurements of
cellular sphingolipid levels showed that dhMotC treatment
lowers ceramide levels. Artificially elevating ceramide levels by
adding exogenous sphingosine or preventing the incorporation
of ceramide into complex sphingolipids through CSG2 inactiva-
tion nearly totally rescued the effects of dhMotC on yeast growth
and on the actin cytoskeleton. These results demonstrate that
inhibition of sphingolipid metabolism is the major, if not the sole
mechanism, of action of dhMotC in yeast.
Our screen did not identify all genes of the sphingolipid
metabolism pathway. Further iterations of the primary screen
might have revealed additional ones, such as the supersensitive
ypk1YPK1 strain found in followup studies. However, func-
tionally redundant genes such as LAC1 and LAG1 cannot be
detected in simple haploinsufficiency screens, and other genes
might escape detection because reduction in gene copy number
does not manifest itself in compromised function. Despite these
limitations, it is likely that at least a subset of heterozygous
deletion strains of any given pathway will be gene dosage-
sensitive and show supersensitivity to drugs in this assay, and will
be sufficient to expose the pathway. The identification of highly
sensitive heterozygous strains, such as lsb5LSB5 and
ygr205wYGR205w, not known to be involved in sphingolipid
biosynthesis might indicate that dhMotC has secondary targets,
although the nearly complete rescue of dhMotC effects by
exogenous sphingosine indicates they must be minor. It is also
possible that lowered expression of these genes is synthetic lethal
with compromised sphingolipid biosynthesis. This issue should
be resolvable in the future, when complete synthetic genetic
interaction maps are available to facilitate the sorting of genes
into those that likely encode pathways targeted by drugs from
those that display synthetic interactions with those pathways (21).
To determine whether yeast drug-induced haploinsufficiency
screening is relevant for finding drug mode of action in human
cells, we sought a simple test with broad applicability. Most drugs
are expected to affect the survival of human cells at high doses.
By analogy to the yeast growth inhibition experiments, we
determined whether the deleterious effects of dhMotC on
human cell survival could be rescued by addition of exogenous
ceramide. Indeed, ceramide provided significant protection
from the effects of dhMotC. However, the extent of protection
was not as high as observed in yeast. One explanation is that
dhMotC might have additional targets in human cells that are
not present in yeast. Alternatively, because ceramide has been
implicated in the regulation of numerous cellular pathways
including apoptosis, senescence and cell-cycle arrest (13, 20), it
is possible that rescue by exogenous ceramide is limited by its
intrinsic toxicity. Nevertheless, this result provides crucial evi-
dence that drug-induced haploinsufficiency studies in yeast can
reveal pathways targeted by drugs in human cells.
In parallel to our own work, Lum et al. (22) have also presented
a yeast drug-induced haploinsufficiency screen to identify drug
mode of action by using a DNA microarray based method with
similar results. The cell-based robotic screening procedure we
Fig. 4. dhMotC targets the sphingolipid biosynthesis pathway. (A) Growth of wild-type strain (BY4743, OD600) as a function of time in YPD liquid culture with
and without treatment of 60 M dhMotC and increasing amounts of DHS as indicated. Growth curves were performed in triplicate and represent the average
of three experiments. Treatment of yeast with DHS does not adversely affect the growth rate of yeast. (B) Actin staining in wild-type cells in the presence or
absence of dhMotC. BY4743 cells were incubated at 25°C in the presence or absence of 60 M dhMotC and 50 M DHS as indicated for 1.5 h. The cells were then
fixed, nuclear staining was visualized by using 4,6-diamidino-2-phenylindole (Upper), and filamentous actin was visualized using rhodamine-phalloidin (Lower).
(C) Growth of wild-type (TDY2037) and csg2 (TDY2038) haploid cells as a function of time in YPD liquid culture with and without 10 M dhMotC treatment.
Growth curves were performed in triplicate and represent the average of three experiments. Haploid cells have an increased sensitivity to dhMotC. (D)
Incorporation of 3H-serine into ceramide after 8 h was measured in both wild-type (TDY 2037) and csg2 (TDY 2038) cells with and without 5 M dhMotC. (E)
Rescue of dhMotC toxicity by ceramide in human cells. MDA-231 cell survival after 24-h exposure to 0 or 10 M dhMotc and 0, 10, or 50 nM C6-ceramide is
expressed as a percentage of untreated controls. The assay was performed in quadruplicate, and error bars represent 1 SD.






have presented can be adapted to screen numerous drug-induced
phenotypes other than growth inhibition, such as activation of
signaling pathways and of transcription, that are not easily
amenable to DNA microarray-based screening. The systematic,
unbiased and genome-wide nature of this technique makes it an
attractive general tool both for discovering drug targets or mode
of action and for revealing ‘‘targetable’’ biological pathways.
Finding new starting points for intervention will contribute to
the development of new therapeutic approaches to disease, a
major stated goal of the Human Genome Project (23).
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